Released Jun 16, 2025, after the close
10-Q filed Jun 16, 2025, 47 days after period end · 0001654954-25-007009
Q2 2025 · 10-Q
Revenue$2.42M$2.42M +1.7% vs Q2 2024−2.2% vs Q1 2025
Net Income$95.35K$95.35K N/M vs Q2 2024+1,017.1% vs Q1 2025
EPS Diluted$0.00$0.00 N/M vs Q2 2024no prior Q1 2025 on file
Gross Profit$818,726+32.4%
Operating Income-$98,322N/M
Operating Cash Flow-$301,590N/M
Free Cash Flowderived-$305,848N/M
Margins · derived
Gross margin33.9%+7.9 pt vs Q2 2024
Operating margin-4.1%+9.1 pt vs Q2 2024
Net margin3.9%+12.9 pt vs Q2 2024
What the release said
The release
Same quarter
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | $2.42M | $2.38M | $4.56M | $4.97M |
| Net Income | $95.35K | -$213.82K | $404.65K | $240.03K |
| EPS Diluted | $0.00 | -$0.01 | — | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR